Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 6/27/14 → 6/26/18 |
Funding
- Merck Sharp and Cohme Corporation: $269,872.00
V160-001-002: A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults
- Rupp, Richard (PI)
Project: Research project